Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
16. |
ECCT/25/07/02 | PROPS Trial Efficacy of probiotic supplementation in preterm and small for gestational age infants. A multi-centre, placebo-controlled, individually-randomised trial (Probiotics in preterm and small for gestational age infants, PROPS trial) |
Principal Investigator(s) 1. Meshack Liru Site(s) in Kenya 1. Homabay County Referral Hospital (Homa Bay county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 3. Kisii Teaching and Referral Hospital (Kisii county) 4. Migori County Referral Hospital (Migori county) |
View |
17. |
ECCT/25/06/02 | Neosep1 An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase. |
Principal Investigator(s) 1. Nayirat Mohamed Dormohamed Site(s) in Kenya 1. Coast General Teaching and Referral Hospital (Mombasa county) |
View |
18. |
ECCT/25/06/01 | Neosep1 An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase. |
Principal Investigator(s) 1. Christine Nafula Manyasi Site(s) in Kenya 1. Mbagathi County Referral Hospital (Nairobi City county) |
View |
19. |
ECCT/25/05/12 | SAFIRE A multicentre open-label, non-inferiority adaptive platform randomised controlled trial to evaluate the efficacy, safety, and tolerability of antimalarials for the treatment of uncomplicated malaria in the first trimester of pregnancy |
Principal Investigator(s) 1. Hellen Barsosio Site(s) in Kenya The Kenya Medical Research Institute (KEMRI), Centre for Global Health Research (CGHR) |
View |
20. |
ECCT/25/05/11 | Sparkle study site-1406 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Doreen Mutua Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Gertrudes Children’s Hospital (Nairobi City county) |
View |